Literature DB >> 25445559

Chemotherapy. After 25 years, therapy for poor-prognosis GCTs advances.

David Killock.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25445559     DOI： 10.1038/nrclinonc.2014.213

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Authors:  Karim Fizazi; Lance Pagliaro; Agnes Laplanche; Aude Fléchon; Josef Mardiak; Lionnel Geoffrois; Pierre Kerbrat; Christine Chevreau; Remy Delva; Frederic Rolland; Christine Theodore; Guilhem Roubaud; Gwenaëlle Gravis; Jean-Christophe Eymard; Jean-Pierre Malhaire; Claude Linassier; Muriel Habibian; Anne-Laure Martin; Florence Journeau; Maria Reckova; Christopher Logothetis; Stephane Culine
Journal:  Lancet Oncol       Date:  2014-11-13       Impact factor: 41.316
  1 in total
  1 in total

Review 1.  The present and future of serum diagnostic tests for testicular germ cell tumours.

Authors:  Matthew J Murray; Robert A Huddart; Nicholas Coleman
Journal:  Nat Rev Urol       Date:  2016-10-18       Impact factor: 14.432
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.